Details for Patent: RE50050

✉ Email this page to a colleague

Patent RE50050 protects CAMZYOS and is included in one NDA.

This patent has sixty-seven patent family members in thirty-nine countries.

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Bristol	CAMZYOS	mavacamten	CAPSULE;ORAL	214998-001	Apr 28, 2022		RX	Yes	No	⤷ Subscribe	⤷ Subscribe	Y	Y			⤷ Subscribe
Bristol	CAMZYOS	mavacamten	CAPSULE;ORAL	214998-002	Apr 28, 2022		RX	Yes	Yes	⤷ Subscribe	⤷ Subscribe	Y	Y			⤷ Subscribe
Bristol	CAMZYOS	mavacamten	CAPSULE;ORAL	214998-003	Apr 28, 2022		RX	Yes	No	⤷ Subscribe	⤷ Subscribe	Y	Y			⤷ Subscribe
Bristol	CAMZYOS	mavacamten	CAPSULE;ORAL	214998-004	Apr 28, 2022		RX	Yes	No	⤷ Subscribe	⤷ Subscribe	Y	Y			⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	3010910	⤷ Subscribe	CR 2023 00034	Denmark	⤷ Subscribe
European Patent Office	3010910	⤷ Subscribe	301253	Netherlands	⤷ Subscribe
European Patent Office	3010910	⤷ Subscribe	PA2023535	Lithuania	⤷ Subscribe
European Patent Office	3010910	⤷ Subscribe	2023C/546	Belgium	⤷ Subscribe
European Patent Office	3010910	⤷ Subscribe	LUC00324	Luxembourg	⤷ Subscribe
European Patent Office	3010910	⤷ Subscribe	122023000063	Germany	⤷ Subscribe
European Patent Office	3010910	⤷ Subscribe	39/2023	Austria	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration